Hmmm, I thought they call Phase 2 the graveyard for clinical drug candidates. Most failures occur in Phase 2.
I would take a glass half full attitude going into a Phase 3.
By that stage the odds of getting to market approval are around 60%.
its amazing , page-10
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.010(0.87%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.15 | $1.13 | $1.027M | 901.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 40934 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 58509 | 6 |
View Market Depth
| Last trade - 12.01pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |